The review is devoted to the recent publications and patents focusing on drug-eluting stents (DESs), which due to
their ability in reducing restenosis are becoming the lead player for the treatment of coronary artery disease (CAD). Various
approaches have been used in development of these medical devices. Most DES architecture includes three components: a
stent platform, a drug delivery vehicle and therapeutic agent; each part has significant impact on the biological performance
of DES. The paper outlines the new developments on drug-eluting stents sustained by patents literature.
Keywords: Bioresorbable, drug-eluting stent, polymer, therapeutic agent.
Rights & PermissionsPrintExport